Published in Clin Cancer Res on July 21, 2009
Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat Rev Cancer (2011) 2.42
Metronomic gemcitabine in combination with sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancer. Mol Cancer Ther (2010) 1.07
Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma. Neoplasia (2010) 1.05
Platelet-activating factor receptor (PAF-R)-dependent pathways control tumour growth and tumour response to chemotherapy. BMC Cancer (2010) 1.00
Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo. Int J Cancer (2011) 0.99
Melanoma biomolecules: independently identified but functionally intertwined. Front Oncol (2013) 0.95
The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models. Int J Cancer (2011) 0.83
Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy. EMBO Mol Med (2014) 0.83
Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer. Mol Cancer Ther (2015) 0.83
First-line metronomic chemotherapy in a metastatic model of spontaneous canine tumours: a pilot study. Invest New Drugs (2011) 0.82
Influence of the implantation site on the sensitivity of patient pancreatic tumor xenografts to Apo2L/TRAIL therapy. Pancreas (2014) 0.80
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol (2000) 9.70
The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer (2004) 6.32
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol (1999) 5.95
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest (2000) 5.52
MDA-MB-435 cells are derived from M14 melanoma cells--a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res Treat (2006) 4.04
A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol (2004) 3.40
Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res (2006) 2.78
Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved. Cancer Biol Ther (2003) 2.61
DTIC (NSC-45388) in malignant melanoma: a perspective. Cancer Treat Rep (1976) 2.59
Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages. Eur J Cancer (2004) 2.20
Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol (2008) 2.10
Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol Cancer Ther (2003) 2.08
Further evidence to support the melanocytic origin of MDA-MB-435. Mol Pathol (2002) 2.04
Development of a preclinical model of spontaneous human melanoma central nervous system metastasis. Cancer Res (2008) 1.99
Chemotherapy for metastatic melanoma: time for a change? Cancer (2007) 1.99
Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol (2003) 1.78
On the development of models in mice of advanced visceral metastatic disease for anti-cancer drug testing. Cancer Metastasis Rev (2007) 1.37
Common origins of MDA-MB-435 cells from various sources with those shown to have melanoma properties. Clin Exp Metastasis (2004) 1.29
Adjuvant therapy of melanoma with interferon: lessons of the past decade. J Transl Med (2008) 1.28
Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model. Cancer Res (2003) 1.22
Continuous low-dose anti-angiogenic/ metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann Oncol (2002) 1.21
Temozolomide for the treatment of metastatic melanoma. Curr Oncol (2007) 1.13
Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia. Cancer Res (2006) 1.02
MDA-MB-435 cells are from melanoma, not from breast cancer. Cancer Chemother Pharmacol (2008) 1.01
MDA-MB-435: the questionable use of a melanoma cell line as a model for human breast cancer is ongoing. Cancer Biol Ther (2007) 1.00
Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma. Cancer (2004) 0.97
Overall and progression-free survival in metastatic melanoma: analysis of a single-institution database. Cancer Control (2006) 0.92
Tumor-targeting Salmonella typhimurium improves cyclophosphamide chemotherapy at maximum tolerated dose and low-dose metronomic regimens in a murine melanoma model. Int J Cancer (2007) 0.92
Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study. Cancer Chemother Pharmacol (2003) 0.91
Choices in adjuvant therapy of melanoma. Cancer Control (2005) 0.86
Chemotherapy for advanced malignant melanoma. Int J Clin Lab Res (1992) 0.85
Dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A phase I-II trial. Am J Clin Oncol (1990) 0.81
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell (2009) 13.09
Angiogenesis as a therapeutic target. Nature (2005) 11.89
Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science (2006) 4.79
The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer (2006) 4.55
Raising the bar for cancer therapy models. Nat Biotechnol (2010) 4.52
Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell (2008) 4.51
Effect of p53 status on tumor response to antiangiogenic therapy. Science (2002) 4.41
Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci U S A (2007) 4.08
Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell (2005) 3.74
Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol (2011) 3.58
Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res (2003) 3.09
Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. Cancer Res (2009) 2.80
Comparative impact of trastuzumab and cyclophosphamide on HER-2-positive human breast cancer xenografts. Clin Cancer Res (2009) 2.79
Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res (2006) 2.78
Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res (2002) 2.69
Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. Proc Natl Acad Sci U S A (2009) 2.66
Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat Rev Cancer (2011) 2.42
Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res (2007) 2.35
miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis. Cancer Cell (2011) 2.30
Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res (2002) 2.27
Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res (2009) 2.23
Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci U S A (2003) 2.20
A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci U S A (2002) 2.16
Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol (2008) 2.06
Development of a preclinical model of spontaneous human melanoma central nervous system metastasis. Cancer Res (2008) 1.99
Versican/PG-M G3 domain promotes tumor growth and angiogenesis. FASEB J (2004) 1.93
Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile. Cancer Biol Ther (2011) 1.87
Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood (2005) 1.80
A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. Mol Cancer Res (2004) 1.79
Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth. Cancer Res (2008) 1.78
Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies. Cancer Res (2004) 1.77
Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. Cancer Res (2006) 1.70
Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood (2006) 1.69
Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin Cancer Res (2002) 1.56
Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy. Cancer Res (2007) 1.52
Id1 restrains p21 expression to control endothelial progenitor cell formation. PLoS One (2007) 1.52
Anti-vascular endothelial growth factor receptor-2 antibody accelerates renal disease in the NZB/W F1 murine systemic lupus erythematosus model. Clin Cancer Res (2005) 1.44
Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development. Clin Cancer Res (2004) 1.40
High-frequency Doppler ultrasound monitors the effects of antivascular therapy on tumor blood flow. Cancer Res (2002) 1.40
Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. Clin Cancer Res (2006) 1.39
On the development of models in mice of advanced visceral metastatic disease for anti-cancer drug testing. Cancer Metastasis Rev (2007) 1.37
Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. Cancer Res (2005) 1.31
Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. Mol Cancer Ther (2010) 1.30
Molecular and cellular biomarkers for angiogenesis in clinical oncology. Drug Discov Today (2007) 1.29
A role for the TGFbeta-Par6 polarity pathway in breast cancer progression. Proc Natl Acad Sci U S A (2009) 1.29
Microultrasound molecular imaging of vascular endothelial growth factor receptor 2 in a mouse model of tumor angiogenesis. Mol Imaging (2007) 1.27
A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens. Cancer Res (2004) 1.27
What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors? Cancer Res (2002) 1.27
Antiadhesive antibodies targeting E-cadherin sensitize multicellular tumor spheroids to chemotherapy in vitro. Mol Cancer Ther (2004) 1.22
Drug rechallenge and treatment beyond progression--implications for drug resistance. Nat Rev Clin Oncol (2013) 1.22
Controlling angiogenesis in breast cancer: a systematic review of anti-angiogenic trials. Cancer Treat Rev (2012) 1.21
Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies. Int J Radiat Oncol Biol Phys (2004) 1.21
Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents. Cancer Res (2009) 1.20
Influence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus cremophor EL-based paclitaxel. Clin Cancer Res (2006) 1.19
High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma. Clin Cancer Res (2006) 1.18
Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor. Clin Cancer Res (2011) 1.15
Endothelial progenitor cells are cellular hubs essential for neoangiogenesis of certain aggressive adenocarcinomas and metastatic transition but not adenomas. Proc Natl Acad Sci U S A (2008) 1.13
Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity. J Clin Oncol (2007) 1.12
Radiation resistance of human melanoma analysed by retroviral insertional mutagenesis reveals a possible role for dopachrome tautomerase. Oncogene (2004) 1.10
A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs. Cancer Res (2013) 1.09
Disruption of cell-cell adhesion enhances antibody-dependent cellular cytotoxicity: implications for antibody-based therapeutics of cancer. Cancer Res (2002) 1.08
High-frequency 3-D color-flow imaging of the microcirculation. Ultrasound Med Biol (2003) 1.07
ras Oncogene triggers up-regulation of cIAP2 and XIAP in intestinal epithelial cells: epidermal growth factor receptor-dependent and -independent mechanisms of ras-induced transformation. J Biol Chem (2005) 1.07
Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models. Mol Cancer Ther (2009) 1.07
Long-term progression and therapeutic response of visceral metastatic disease non-invasively monitored in mouse urine using beta-human choriogonadotropin secreting tumor cell lines. Mol Cancer Ther (2008) 1.06
Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy. Clin Cancer Res (2005) 1.06
Combined blockade of integrin-α4β1 plus cytokines SDF-1α or IL-1β potently inhibits tumor inflammation and growth. Cancer Res (2011) 1.06
Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma. Neoplasia (2010) 1.05
Vascular endothelial growth factor isoform expression as a determinant of blood vessel patterning in human melanoma xenografts. Cancer Res (2002) 1.05
Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide. Neoplasia (2011) 1.04